Anatara Lifesciences trading on ASX


By Dylan Bushell-Embling
Thursday, 16 October, 2014

Anatara Lifesciences has listed on the ASX following its $7 million IPO. The shares started trading today under the ticker code ANR.

Anatara closed its oversubscribed IPO last week to help raise funds for the commercial development of non-antibiotic diarrhoea therapy Detach. The shares were priced at $0.50.

The company is focused on commercialising Detach in pigs first, and plans to use part of the proceeds to fund registration of the product for use in pigs in Australia, the EU and the US.

More long-term plans include expanding its use to other livestock and developing a version for human applications.

“This is an exciting day for Anatara as we take our first steps as a public company addressing an unmet need for effective non-antibiotic treatments and medicines,” Anatara Chairman Dr Mel Bridges said.

“We look forward to updating shareholders on our progress with Detach and seeing this important and innovative product enter the market.”

Anatara Lifesciences (ASX:ANR) shares were trading at 0.375 as of around 1.30 pm on Thursday.

Related News

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...

Archer completes potassium sensing alpha prototype

Quantum technology company Archer Materials Limited has developed an early Biochip prototype...

Farm animals and aquaculture cryopreservation partnership announced

Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd